| Literature DB >> 28689157 |
Anne-Sophie Salabert1, Charlotte Fontan2, Caroline Fonta3, Mathieu Alonso4, Najat Loukh5, Marie Bernadette Delisle6, Mathieu Tafani7, Pierre Payoux8.
Abstract
In this study, we describe the radiosynthesis of [18F]AV1451 in terms of its pharmaceutical quality and characterise its physical and biological properties. We performed an in vitro serum stability study in fresh human plasma and a plasma protein binding study. The radiochemical yield was 24% (decay corrected), and the product met all regulatory quality requirements. We found that this compound is stable in fresh human plasma and binds tightly to plasma proteins, especially lipoproteins.Entities:
Keywords: Neurodegeneration; Plasma protein binding; Radiopharmaceutical drug; TAU protein
Mesh：
Substances：
Year: 2017 PMID： 28689157 DOI： 10.1016/j.apradiso.2017.06.032
Source DB: PubMed Journal: Appl Radiat Isot ISSN： 0969-8043 Impact factor: 1.513